Benign Cutaneous Eruptions After Transplantation

  • Lucinda Kohn
  • Oscar R. Colegio


This chapter explores cutaneous diseases that are present in immunosuppressed solid organ transplant recipients. A chronologic approach begins with the cutaneous manifestations of end-stage kidney and liver disease. Subsequently, the cutaneous complications of induction therapy followed by posttransplant immunosuppression are organized by immunosuppressive agent and time to onset of each cutaneous eruption.


Chronic immunosuppression Gingival enlargement Acneiform eruption Kidney failure Liver failure 


  1. 1.
    Udayakumar P, Balasubramanian S, Ramalingam KS, Lakshmi C, Srinivas CR, Mathew AC. Cutaneous manifestations in patients with chronic renal failure on hemodialysis. Indian J Dermatol Venereol Leprol. 2006;72(2):119–25.CrossRefPubMedGoogle Scholar
  2. 2.
    Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis. 2007;50(1):11–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Pisoni RL, Wikstrom B, Elder SJ, Akizawa T, Asano Y, Keen ML, Saran R, Mendelssohn DC, Young EW, Port FK. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21(12):3495–505.CrossRefPubMedGoogle Scholar
  4. 4.
    Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol. 2009;5(3):157–70.PubMedGoogle Scholar
  5. 5.
    Kimmel M, Alscher DM, Dunst R, Braun N, Machleidt C, Kiefer T, Stulten C, van der Kuip H, Pauli-Magnus C, Raub U, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21(3):749–55.CrossRefPubMedGoogle Scholar
  6. 6.
    Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, laina A. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet. 1996;348(9041):1552–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Robinson-Bostom L, DiGiovanna JJ. Cutaneous manifestations of end-stage renal disease. J Am Acad Dermatol. 2000;43(6):975–86;quiz 87–90.CrossRefPubMedGoogle Scholar
  8. 8.
    Morton CA, Henderson IS, Jones MC, Lowe JG. Acquired perforating dermatosis in a British dialysis population. Br J Dermatol. 1996;135(5):671–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Hood AF, Hardegen GL, Zarate AR, Nigra TP, Gelfand MC. Kyrle’s disease in patients with chronic renal failure. Arch Dermatol. 1982;118(2):85–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Patterson JW. The perforating disorders. J Am Acad Dermatol. 1984;10(4):561–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Oh DH, Eulau D, Tokugawa DA, McGuire JS, Kohler S. Five cases of calciphylaxis and a review of the literature. J Am Acad Dermatol. 1999;40(6 Pt 1):979–87.CrossRefPubMedGoogle Scholar
  12. 12.
    Hafner J, Keusch G, Wahl C, Burg G. Calciphylaxis: a syndrome of skin necrosis and acral gangrene in chronic renal failure. VASA Zeitschrift fur Gefasskrankheiten. 1998;27(3):137–43.PubMedGoogle Scholar
  13. 13.
    Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, Smith GP, Kroshinsky D. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013;149(8):946–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Basile C, Montanaro A, Masi M, Pati G, De Maio P, Gismondi A. Hyperbaric oxygen therapy for calcific uremic arteriolopathy: a case series. J Nephrol. 2002;15(6):676–80.PubMedGoogle Scholar
  15. 15.
    Savoia F, Gaddoni G, Patrizi A, Misciali C, Odorici G, Tampieri G, Tampieri E, Cantelli S, Aldi M. Calciphylaxis in dialysis patients, a severe disease poorly responding to therapies: report of 4 cases. G Ital Dermatol Venereol. 2013;148(5):531–6.PubMedGoogle Scholar
  16. 16.
    Alagheband M, Engineer L. Lithium and halogenoderma. Arch Dermatol. 2000;136(1):126–7.CrossRefPubMedGoogle Scholar
  17. 17.
    Vaillant L, Pengloan J, Blanchier D, De Muret A, Lorette G. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. Clin Exp Dermatol. 1990;15(3):232–3.CrossRefPubMedGoogle Scholar
  18. 18.
    Bolognia J, Jorizzo JL, Schaffer JV. Philadelphia; London: Elsevier Saunders; 2012:1 online resource (2 v. in 1).Google Scholar
  19. 19.
    Cordoliani F, Rybojad M, Morel P, Puissant A. Halogenoderma and monoclonal gammopathy. J Am Acad Dermatol. 1991;25(6 Pt 1):1099.CrossRefPubMedGoogle Scholar
  20. 20.
    Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis. 2012;16(2):331–46.CrossRefPubMedGoogle Scholar
  21. 21.
    Terry R. White nails in hepatic cirrhosis. Lancet. 1954;266(6815):757–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Tanriover B, Chuang P, Fishbach B, Helderman JH, Kizilisik T, Nylander W, Shaffer D, Langone AJ. Polyclonal antibody-induced serum sickness in renal transplant recipients: treatment with therapeutic plasma exchange. Transplantation. 2005;80(2):279–81.CrossRefPubMedGoogle Scholar
  23. 23.
    Lundquist AL, Chari RS, Wood JH, Miller GG, Schaefer HM, Raiford DS, Wright KJ, Gorden DL. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl. 2007;13(5):647–50.CrossRefPubMedGoogle Scholar
  24. 24.
    Steiner RW, Awdishu L. Steroids in kidney transplant patients. Semin Immunopathol. 2011;33(2):157–67.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Shibasaki F, Hallin U, Uchino H. Calcineurin as a multifunctional regulator. J Biochem. 2002;131(1):1–15.CrossRefPubMedGoogle Scholar
  26. 26.
    Yu HJ, Lee SK, Son SJ, Kim YS, Yang HY, Kim JH. Steroid acne vs. Pityrosporum folliculitis: the incidence of Pityrosporum ovale and the effect of antifungal drugs in steroid acne. Int J Dermatol. 1998;37(10):772–7.CrossRefPubMedGoogle Scholar
  27. 27.
    Mills OH Jr, Leyden JJ, Kligman AM. Tretinoin treatment of steroid acne. Arch Dermatol. 1973;108(3):381–4.CrossRefPubMedGoogle Scholar
  28. 28.
    Mahe E, Morelon E, Lechaton S, Drappier JC, de Prost Y, Kreis H, Bodemer C. Acne in recipients of renal transplantation treated with sirolimus: clinical, microbiologic, histologic, therapeutic, and pathogenic aspects. J Am Acad Dermatol. 2006;55(1):139–42.CrossRefPubMedGoogle Scholar
  29. 29.
    Liu LS, McNiff JM, Colegio OR. Palmoplantar peeling secondary to sirolimus therapy. Am J Transplant. 2014;14(1):221–5.CrossRefPubMedGoogle Scholar
  30. 30.
    Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clin Transpl. 2010;24(2):149–56.CrossRefGoogle Scholar
  31. 31.
    Scully C. Clinical practice. Aphthous ulceration. N Engl J Med. 2006;355(2):165–72.CrossRefPubMedGoogle Scholar
  32. 32.
    Sonis S, Treister N, Chawla S, Demetri G, Haluska F. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer. 2010;116(1):210–5.PubMedGoogle Scholar
  33. 33.
    MacDonald AS, Group RGS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001;71(2):271–80.CrossRefPubMedGoogle Scholar
  34. 34.
    Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet. 2000;356(9225):194–202.CrossRefPubMedGoogle Scholar
  35. 35.
    van Gelder T, ter Meulen CG, Hene R, Weimar W, Hoitsma A. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation. 2003;75(6):788–91.CrossRefPubMedGoogle Scholar
  36. 36.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation. 2009;87(2):233–42.CrossRefPubMedGoogle Scholar
  37. 37.
    Olczak-Kowalczyk D, Pawlowska J, Cukrowska B, Kluge P, Witkowska-Vogtt E, Dzierzanowska-Fangrat K, Wrzesniewska D, Smirska E, Grenda R. Local presence of cytomegalovirus and Candida species vs oral lesions in liver and kidney transplant recipients. Ann Transplant. 2008;13(4):28–33.PubMedGoogle Scholar
  38. 38.
    Sharma S, Dasroy SK. Images in clinical medicine. Gingival hyperplasia induced by phenytoin. N Engl J Med. 2000;342(5):325.CrossRefPubMedGoogle Scholar
  39. 39.
    Yu DS, Lee YB. Images in clinical medicine. Medication-induced gingival hypertrophy. N Engl J Med. 2009;360(2):e2.CrossRefPubMedGoogle Scholar
  40. 40.
    Nakib N, Ashrafi SS. Drug-induced gingival overgrowth. Dis Mon. 2011;57(4):225–30.CrossRefPubMedGoogle Scholar
  41. 41.
    Hallmon WW, Rossmann JA. The role of drugs in the pathogenesis of gingival overgrowth. A collective review of current concepts. Periodontology. 1999;21:176–96.CrossRefGoogle Scholar
  42. 42.
    Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol. 1996;23(3 Pt 1):165–75.CrossRefPubMedGoogle Scholar
  43. 43.
    Langer RM, Kahan BD. Incidence, therapy, and consequences of lymphocele after sirolimus-cyclosporine-prednisone immunosuppression in renal transplant recipients. Transplantation. 2002;74(6):804–8.CrossRefPubMedGoogle Scholar
  44. 44.
    Desai N, Heenan S, Mortimer PS. Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism. Br J Dermatol. 2009;160(6):1322–6.CrossRefPubMedGoogle Scholar
  45. 45.
    Huber S, Bruns CJ, Schmid G, Hermann PC, Conrad C, Niess H, Huss R, Graeb C, Jauch KW, Heeschen C, et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int. 2007;71(8):771–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Kobayashi S, Kishimoto T, Kamata S, Otsuka M, Miyazaki M, Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci. 2007;98(5):726–33.CrossRefPubMedGoogle Scholar
  47. 47.
    Wysocki GP, Daley TD. Hypertrichosis in patients receiving cyclosporine therapy. Clin Exp Dermatol. 1987;12(3):191–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Taylor M, Ashcroft AT, Messenger AG. Cyclosporin A prolongs human hair growth in vitro. J Invest Dermatol. 1993;100(3):237–9.CrossRefPubMedGoogle Scholar
  49. 49.
    Gafter-Gvili A, Sredni B, Gal R, Gafter U, Kalechman Y. Cyclosporin A-induced hair growth in mice is associated with inhibition of calcineurin-dependent activation of NFAT in follicular keratinocytes. Am J Physiol Cell Physiol. 2003;284(6):C1593–603.CrossRefPubMedGoogle Scholar
  50. 50.
    Gafter-Gvili A, Kalechman Y, Sredni B, Gal R, Gafter U. Cyclosporin A-induced hair growth in mice is associated with inhibition of hair follicle regression. Arch Dermatol Res. 2004;296(6):265–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Boudou P, Fiet J, Vexiau P, Villette JM, Hardy N, Dreux C. Greater conversion of testosterone to 5 alpha-dihydrotestosterone, reflecting increased peripheral 5 alpha-reductase activity in nude mice treated with high doses of cyclosporine A. J Steroid Biochem. 1990;36(6):597–601.CrossRefPubMedGoogle Scholar
  52. 52.
    Thorp M, DeMattos A, Bennett W, Barry J, Norman D. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. Transplantation. 2000;69(6):1218–20.CrossRefPubMedGoogle Scholar
  53. 53.
    Kim HC, Hwang EA, Han SY, Park SB, Kim HT, Cho WH. Primary immunosuppression with tacrolimus in kidney transplantation: three-year follow-up in a single center. Transplant Proc. 2004;36(7):2082–3.CrossRefPubMedGoogle Scholar
  54. 54.
    Tricot L, Lebbe C, Pillebout E, Martinez F, Legendre C, Thervet E. Tacrolimus-induced alopecia in female kidney-pancreas transplant recipients. Transplantation. 2005;80(11):1546–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Haycox CL, Kim S, Fleckman P, Smith LT, Piepkorn M, Sundberg JP, Howell DN, Miller SE. Trichodysplasia spinulosa—a newly described folliculocentric viral infection in an immunocompromised host. J Investig Dermatol Symp Proc. 1999;4(3):268–71.CrossRefPubMedGoogle Scholar
  56. 56.
    van der Meijden E, Janssens RW, Lauber C, Bouwes Bavinck JN, Gorbalenya AE, Feltkamp MC. Discovery of a new human polyomavirus associated with trichodysplasia spinulosa in an immunocompromized patient. PLoS Pathog. 2010;6(7):e1001024.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    van der Meijden E, Kazem S, Burgers MM, Janssens R, Bouwes Bavinck JN, de Melker H, Feltkamp MC. Seroprevalence of trichodysplasia spinulosa-associated polyomavirus. Emerg Infect Dis. 2011;17(8):1355–63.PubMedPubMedCentralGoogle Scholar
  58. 58.
    Holzer AM, Hughey LC. Trichodysplasia of immunosuppression treated with oral valganciclovir. J Am Acad Dermatol. 2009;60(1):169–72.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G, Ranieri E, Gesualdo L, Schena FP, Grandaliano G. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005;352(13):1317–23.CrossRefPubMedGoogle Scholar
  60. 60.
    Mbulaiteye SM, Engels EA. Kaposi's sarcoma risk among transplant recipients in the United States (1993-2003). Int J Cancer. 2006;119(11):2685–91.CrossRefPubMedGoogle Scholar
  61. 61.
    Shepherd FA, Maher E, Cardella C, Cole E, Greig P, Wade JA, Levy G. Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol. 1997;15(6):2371–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Ma T, Jham BC, Hu J, Friedman ER, Basile JR, Molinolo A, Sodhi A, Montaner S. Viral G protein-coupled receptor up-regulates Angiopoietin-like 4 promoting angiogenesis and vascular permeability in Kaposi's sarcoma. Proc Natl Acad Sci U S A. 2010;107(32):14363–8.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Sodhi A, Montaner S, Patel V, Zohar M, Bais C, Mesri EA, Gutkind JS. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Res. 2000;60(17):4873–80.PubMedGoogle Scholar
  64. 64.
    Campistol JM, Schena FP. Kaposi's sarcoma in renal transplant recipients—the impact of proliferation signal inhibitors. Nephrol Dial Transplant. 2007;22(Suppl 1):i17–22.CrossRefPubMedGoogle Scholar
  65. 65.
    Lebbe C, Euvrard S, Barrou B, Pouteil-Noble C, Garnier JL, Glotz D, Legendre C, Frances C. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant. 2006;6(9):2164–8.CrossRefPubMedGoogle Scholar
  66. 66.
    Wasywich CA, Croxson MC, van Doornum GJ, Coverdale HA, Ruygrok PN. Sirolimus for Kaposi’s sarcoma. J Heart Lung Transplant. 2006;25(6):726–9.CrossRefPubMedGoogle Scholar
  67. 67.
    Dyall-Smith D, Trowell H, Dyall-Smith ML. Benign human papillomavirus infection in renal transplant recipients. Int J Dermatol. 1991;30(11):785–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Boyle J, MacKie RM, Briggs JD, Junor BJ, Aitchison TC. Cancer, warts, and sunshine in renal transplant patients. A case-control study. Lancet. 1984;1(8379):702–5.CrossRefPubMedGoogle Scholar
  69. 69.
    Schmook T, Nindl I, Ulrich C, Meyer T, Sterry W, Stockfleth E. Viral warts in organ transplant recipients: new aspects in therapy. Br J Dermatol. 2003;149(Suppl 66):20–4.CrossRefPubMedGoogle Scholar
  70. 70.
    Blessing K, McLaren KM, Benton EC, Barr BB, Bunney MH, Smith IW, Beveridge GW. Histopathology of skin lesions in renal allograft recipients—an assessment of viral features and dysplasia. Histopathology. 1989;14(2):129–39.CrossRefPubMedGoogle Scholar
  71. 71.
    de Lima AM, da Rocha SP, Reis Filho EG, Eid DR, Reis CM. Study of dermatoses in kidney transplant patients. An Bras Dermatol. 2013;88(3):361–7.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Chovatiya RJ, Colegio OR. Demodicosis in renal transplant recipients. Am J Transplant. 2016;16(2):712–6.CrossRefPubMedGoogle Scholar
  73. 73.
    Salim A, Reece SM, Smith AG, Harrison D, Ramsay HM, Harden PN, Fryer AA. Sebaceous hyperplasia and skin cancer in patients undergoing renal transplant. J Am Acad Dermatol. 2006;55(5):878–81.CrossRefPubMedGoogle Scholar
  74. 74.
    de Berker DA, Taylor AE, Quinn AG, Simpson NB. Sebaceous hyperplasia in organ transplant recipients: shared aspects of hyperplastic and dysplastic processes? J Am Acad Dermatol. 1996;35(5 Pt 1):696–9.CrossRefPubMedGoogle Scholar
  75. 75.
    McDonald SK, Goh MS, Chong AH. Successful treatment of cyclosporine-induced sebaceous hyperplasia with oral isotretinoin in two renal transplant recipients. Australas J Dermatol. 2011;52(3):227–30.CrossRefPubMedGoogle Scholar
  76. 76.
    Perrett CM, McGregor J, Barlow RJ, Karran P, Proby C, Harwood CA. Topical photodynamic therapy with methyl aminolevulinate to treat sebaceous hyperplasia in an organ transplant recipient. Arch Dermatol. 2006;142(6):781–2.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologyUniversity of California San Francisco School of MedicineSan FranciscoUSA
  2. 2.Department of DermatologyYale School of MedicineNew HavenUSA

Personalised recommendations